Abbott Stock: ABT Raises 2026 EPS Outlook to $5.45-$5.60 After Q2 Beat

What Abbott's Raised 2026 EPS Guidance Changed

Abbott posted second-quarter sales growth of 4.8% and earnings per share of $1.31, then used that result to raise its full-year 2026 profit outlook to a range of $5.45 to $5.60 per share. The company also pointed to comparable sales growth of 6.5% to 7.5% for the year and highlighted new product launches across its business as supporting the higher forecast.

Why Abbott Stock Is in Focus

Abbott is in focus because a guidance raise tied to an actual quarterly beat is a direct signal that management sees the current momentum, not just the last three months, continuing through the rest of the year. Abbott's business spans medical devices, diagnostics, nutrition products like Similac, and established pharmaceuticals, so a broad-based guidance raise implies strength is showing up across more than one division rather than in a single product line.

Which Stocks, and Why

The direct beneficiary is Abbott itself. A raised full-year EPS range gives investors and analysts a higher bar for the company's own performance, and it reflects management's confidence that first-half trends, including new product launches, will hold up through the back half of the year. There is no credible one-step channel from this result to any other company in the medical-device or diagnostics space, since the guidance raise is specific to Abbott's own product mix and execution rather than a market-wide shift in demand or pricing.

What to Watch

The next data points are Abbott's third-quarter results and any commentary on whether the new product launches referenced in this guidance are tracking ahead of, in line with, or behind plan. A widening or narrowing of the $5.45 to $5.60 EPS range in future updates would be the clearest signal of whether this momentum is holding.